Loading...
XNAS
KRSA
Market cap15mUSD
, Last price  
USD
Name

CYCLERION THERAPEUTICS

Chart & performance

D1W1MN
XNAS:KRSA chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
-21.24%
Rev. gr., 5y
-2.01%
Revenues
2m
+3.70%
0004,507,0002,296,0003,320,000297,00002,000,0002,074,000
Net income
-4m
L+15.41%
-63,554,000-93,922,000-115,252,000-123,008,000-77,802,000-51,647,000-44,078,000-5,263,000-3,057,000-3,528,000
CFO
-3m
L-23.52%
-49,874,000-81,218,000-97,503,000-102,215,000-72,490,000-36,517,000-40,611,000-21,245,000-4,333,000-3,314,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
URL
https://www.cyclerion.com/
IPO date
Mar 18, 2019
Employees
16
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT